Trilaciclib from BOC Sciences

Supplier Page

Supplier Page from
BOC Sciences for
Trilaciclib

Description

Trilaciclib is a CDK4/6 inhibitor with IC50 of 1 nM and 4 nM, respectively. It is developed to reduce the burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer